|
The Cochrane Collaboration
Cochrane Reviews |
| Explore | New + Updated | Other languages |
|
 |
Intravenous immunoglobulin for multifocal motor neuropathyvan Schaik IN, van den Berg LH, de Haan R, Vermeulen M
Bookmark this:
     more ...
SummaryIntravenous immunoglobulin treatment improves strength significantly more often than placeboMultifocal motor neuropathy is a rare condition causing progressive weakness of the limbs. The arms and especially the hands, are more commonly involved than the legs. The usual treatment for multifocal motor neuropathy is infusion of immunoglobulin (antibodies purified from the blood) into a vein. Evidence from four randomised controlled trials showed that people treated with intravenous immunoglobulin had significant improvements in strength. Improvement in disability was also seen but was not significant. Side effects were common but were mild and transient.
This is a Cochrane review abstract and plain language summary, prepared and maintained by The Cochrane Collaboration, currently published in The Cochrane Database of Systematic Reviews 2010 Issue 1, Copyright © 2010 The Cochrane Collaboration. Published by John Wiley and Sons, Ltd.. The full text of the review is available in The Cochrane Library (ISSN 1464-780X).
This version first published online:
April 20. 2005 AbstractBackgroundMultifocal motor neuropathy is a rare, probably immune mediated disorder characterised by slowly progressive, asymmetric, distal weakness of one or more limbs with no objective loss of sensation. It may cause prolonged periods of disability. The treatment options for multifocal motor neuropathy are sparse. Patients with multifocal motor neuropathy do not usually respond to steroids or plasma exchange, and may even worsen with these treatments. Many uncontrolled studies have suggested a beneficial effect of intravenous immunoglobulin. ObjectivesTo review systematically the evidence from randomised controlled trials concerning the efficacy and safety of intravenous immunoglobulin in multifocal motor neuropathy. Search strategyWe used the search strategy of the Cochrane Neuromuscular Disease Review Group to search the Disease Group register (searched March 2007), MEDLINE (January 1990 to March 2007), EMBASE (January 1990 to March 2007) and ISI (January 1990 to March 2007) databases for randomised controlled trials. Selection criteriaRandomised controlled studies examining the effects of any dose of intravenous immunoglobulin versus placebo in patients with definite or probable multifocal motor neuropathy. Data collection and analysisTwo authors reviewed literature searches to identify potentially relevant trials, scored their quality and extracted data independently. For dichotomous data, we calculated relative risks, and for continuous data, effect sizes and weighted pooled effect sizes. Statistical uncertainty was expressed with 95% confidence intervals. Main resultsFour randomised controlled trials including a total of 34 patients were suitable for this systematic review. Strength improved in 78% of patients treated with intravenous immunoglobulin and only 4% of placebo-treated patients. Disability improved in 39% of patients after intravenous immunoglobulin treatment and in 11% after placebo (statistically not significantly different). Mild, transient side effects were reported in 71% of intravenous immunoglobulin treated patients. Serious side effects were not encountered. Authors' conclusionsLimited evidence from randomised controlled trials shows that intravenous immunoglobulin has a beneficial effect on strength. There was a non-significant trend towards improvement in disability. More research is needed to discover whether intravenous immunoglobulin improves disability and is cost-effective. |